Sedative drugs modulate the neuronal activity in the subthalamic nucleus of parkinsonian patients

Amit Benady, Sean Zadik, Dan Eimerl, Sami Heymann, Hagai Bergman, Zvi Israel, Aeyal Raz, Amit Benady, Sean Zadik, Dan Eimerl, Sami Heymann, Hagai Bergman, Zvi Israel, Aeyal Raz

Abstract

Microelectrode recording (MER) is often used to identify electrode location which is critical for the success of deep brain stimulation (DBS) treatment of Parkinson's disease. The usage of anesthesia and its' impact on MER quality and electrode placement is controversial. We recorded neuronal activity at a single depth inside the Subthalamic Nucleus (STN) before, during, and after remifentanil infusion. The root mean square (RMS) of the 250-6000 Hz band-passed signal was used to evaluate the regional spiking activity, the power spectrum to evaluate the oscillatory activity and the coherence to evaluate synchrony between two microelectrodes. We compare those to new frequency domain (spectral) analysis of previously obtained data during propofol sedation. Results showed Remifentanil decreased the normalized RMS by 9% (P < 0.001), a smaller decrease compared to propofol. Regarding the beta range oscillatory activity, remifentanil depressed oscillations (drop from 25 to 5% of oscillatory electrodes), while propofol did not (increase from 33.3 to 41.7% of oscillatory electrodes). In the cases of simultaneously recorded oscillatory electrodes, propofol did not change the synchronization while remifentanil depressed it. In conclusion, remifentanil interferes with the identification of the dorsolateral oscillatory region, whereas propofol interferes with RMS identification of the STN borders. Thus, both have undesired effect during the MER procedure.Trial registration: NCT00355927 and NCT00588926.

Conflict of interest statement

AR is a consultant for Medtronic (unrelated to the current manuscript), HB is a consultant for Alpha Omega and had received travel honoraria from Medtronic and Boston Scientific (unrelated to the current manuscript). None of the other authors reported any conflict of interest.

Figures

Figure 1
Figure 1
Effects of sedation on the global spiking activity in the STN. A: Raw data examples from a single trajectory. Top: before STN entry (presumably in white matter). Second line: inside the STN, before remifentanil administration. Third line: inside the STN, at the same location during remifentanil administration (patient sedated to the desired level). Bottom: inside the STN, at the same location, after remifentanil administration stopped, patient awake and responsive. All traces are 30 s long and presented with the same y scale. BC: Examples of normalized root mean square (RMS) changes during propofol (B) and remifentanil (C) administration. X-axis = time (min); Y-axis = normalized RMS. Gray bars above the graphs indicates duration of drug administration. DE: Population normalized. RMS. Aligned to the beginning of propofol (D) or remifentanil (E) administration. X-axis = time (min); Y-axis = normalized RMS. Subplots B and D are modified from Raz et al. Anesth Analg 2010; 111:1,285–9 for easy comparison of propofol and remifentanil effects.
Figure 2
Figure 2
Effects of sedation on oscillatory activity in the STN. Green and red frames (A, B) represent two cells which are also depicted in figures C and D for propofol and remifentanil, respectively. A: Raw data examples from two distinct cells. Top row: First cell, before propofol administration. Second row: Second cell, before propofol administration. Third row: First cell, during propofol administration (patient sedated to the desired level). Bottom row: Second cell, during propofol administration (patient sedated to the desired level). All traces are 10 s long and presented with the same y scale. B: The same as A, for remifentanil administration. C: Average power spectrum (left) and coherence (right) of 30 s of neural (multi-unit) activity in a single location measured from one patient before (top) and during (bottom) administration of propofol. It can be seen that no reduction of the beta power oscillations or coherence was observed. D: Same as C but with administration of remifentanil, measured from a different patient. It can be seen that one of the cells lost its’ oscillatory behavior, and the previously robust synchronization disappeared. E: Power spectrum of the multi-unit activity recorded by a single electrode measured around the time of propofol administration. It can be seen oscillatory activity in the beta power increased during propofol sedation. F: Same as E, but around the time of remifentanil administration. It can be seen that significant reduction in the beta power was observed during remifentanil administration. G: Coherence of the mutli-unit activity of two simultaneously recorded electrodes measured around the time of propofol administration. It can be seen that there is a significant coherence between the two electrodes which is maintained under sedation with propofol. H: Same as G but during administration of remifentanil. It can be seen that there is a significant coherence between the two electrodes which is depressed after remifentanil administration. For EH, x-axis = time (min); y-axis = frequency (Hz) and color code represents power (E, F) or coherence (G, H). Time of sedative drug administration (propofol—left column, remifentanil—right column) is marked by a vertical line.

References

    1. Hickey P, Stacy M. Deep brain stimulation: a paradigm shifting approach to treat Parkinson's disease. Front. Neurosci. 2016;10:173. doi: 10.3389/fnins.2016.00173.
    1. Kuhn AA, Kempf F, Brucke C, Gaynor Doyle L, Martinez-Torres I, Pogosyan A, et al. High-frequency stimulation of the subthalamic nucleus suppresses oscillatory beta activity in patients with Parkinson's disease in parallel with improvement in motor performance. J. Neurosci. 2008;28(24):6165–6173. doi: 10.1523/JNEUROSCI.0282-08.2008.
    1. Gross,R. E., Krack, P., Rodriguez-Oroz, M. C., Rezai, A. R., & Benabid, A. Electrophysiological mapping for the implantation of deep brain stimulators for Parkinson's disease and tremor. Mov. Dis.21(S14), 259–283 (2006).
    1. Zaidel A, Spivak A, Shpigelman L, Bergman H, Israel Z. Delimiting subterritories of the human subthalamic nucleus by means of microelectrode recordings and a Hidden Markov Model. Mov. Disord. 2009;24(12):1785–1793. doi: 10.1002/mds.22674.
    1. Valsky D, Marmor-Levin O, Deffains M, Eitan R, Blackwell KT, Bergman H, et al. Stop! border ahead: A utomatic detection of subthalamic exit during deep brain stimulation surgery. Mov. Disord. 2017;32(1):70–79. doi: 10.1002/mds.26806.
    1. Hertel F, Züchner M, Weimar I, Gemmar P, Noll B, Bettag M, et al. Implantation of electrodes fordeep brain stimulation of the subthalamic nucleus in advanced parkinson's disease with the aid of intraoperative microrecording undergeneral anesthesia. Neurosurgery. 2006;59(5):E1138–E1138. doi: 10.1227/01.NEU.0000245603.77075.55.
    1. Kalenka A, Schwarz A. Anaesthesia and Parkinson's disease: How to manage with new therapies? Curr. Opin. Anaesthesiol. 2009;22(3):419–424. doi: 10.1097/ACO.0b013e32832a4b31.
    1. Bos, M. J., Buhre, W., Temel, Y., Joosten, E. A. J., Absalom, A. R., & Absalom, M. L. F. Effect of anesthesia on microelectrode recordings during deep brain stimulation surgery: A narrative review. J. Neurosurg. Anesth. 10.1097/ANA.0000000000000673 (2020).
    1. Zaidel A, Spivak A, Grieb B, Bergman H, Israel Z. Subthalamic span of β oscillations predicts deep brain stimulation efficacy for patients with Parkinson’s disease. Brain. 2010;133(7):2007–2021. doi: 10.1093/brain/awq144.
    1. Pogosyan A, Gaynor LD, Eusebio A, Brown P. Boosting cortical activity at beta-band frequencies slows movement in humans. Curr. Biol. 2009;19(19):1637–1641. doi: 10.1016/j.cub.2009.07.074.
    1. Kilavik BE, Zaepffel M, Brovelli A, MacKay WA, Riehle A. The ups and downs of beta oscillations in sensorimotor cortex. Exp. Neurol. 2013;245:15–26. doi: 10.1016/j.expneurol.2012.09.014.
    1. Rubchinsky LL, Park C, Worth RM. Intermittent neural synchronization in Parkinson’s disease. Nonlinear Dyn. 2012;68(3):329–346. doi: 10.1007/s11071-011-0223-z.
    1. Heinrichs-Graham E, Kurz MJ, Becker KM, Santamaria PM, Gendelman HE, Wilson TW. Hypersynchrony despite pathologically reduced beta oscillations in patients with Parkinson's disease: a pharmaco-magnetoencephalography study. J. Neurophysiol. 2014;112(7):1739–1747. doi: 10.1152/jn.00383.2014.
    1. Brown P. Bad oscillations in Parkinson’s disease. Parkinson’s Disease and Related Disorders: Springer; 2006. p. 27–30.
    1. Little S, Brown P. The functional role of beta oscillations in Parkinson's disease. Parkinsonism Relat. Disord. 2014;20:S44–S48. doi: 10.1016/S1353-8020(13)70013-0.
    1. Kühn AA, Kupsch A, Schneider G, Brown P. Reduction in subthalamic 8–35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease. Eur. J. Neurosci. 2006;23(7):1956–1960. doi: 10.1111/j.1460-9568.2006.04717.x.
    1. Raz A, Eimerl D, Zaidel A, Bergman H, Israel Z. Propofol decreases neuronal population spiking activity in the subthalamic nucleus of Parkinsonian patients. Anesth. Analg. 2010;111(5):1285–1289. doi: 10.1213/ANE.0b013e3181f565f2.
    1. Mathews L, Camalier CR, Kla KM, Mitchell MD, Konrad PE, Neimat JS, et al. The effects of dexmedetomidine on microelectrode recordings of the subthalamic nucleus during deep brain stimulation surgery: A retrospective analysis. Stereotact. Funct. Neurosurg. 2017;95(1):40–48. doi: 10.1159/000453326.
    1. Lettieri C, Rinaldo S, Devigili G, Pauletto G, Verriello L, Budai R, et al. Deep brain stimulation: Subthalamic nucleus electrophysiological activity in awake and anesthetized patients. Clin. Neurophysiol. 2012;123(12):2406–2413. doi: 10.1016/j.clinph.2012.04.027.
    1. Moll CK, Payer S, Gulberti A, Sharrott A, Zittel S, Boelmans K, et al. STN stimulation in general anaesthesia Evidence beyond ‘evidence-based medicine’. Stereotactic and functional neurosurgery. Berlin: Springer; 2013. pp. 19–25.
    1. Moshel S, Shamir RR, Raz A, de Noriega FR, Eitan R, Bergman H, et al. Subthalamic nucleus long-range synchronization—an independent hallmark of human Parkinson's disease. Front. Syst. Neurosci. 2013;7:79. doi: 10.3389/fnsys.2013.00079.
    1. Chakrabarti R, Ghazanwy M, Tewari A. Anesthetic challenges for deep brain stimulation: A systematic approach. N. Am. J. Med. Sci. 2014;6(8):359–369. doi: 10.4103/1947-2714.139281.
    1. Ho, A. L., Ali, R., Connolly, I. D., Henderson, J. M., Dhall, R., & Stein, S. C., et al. Awake versus asleep deep brain stimulation for Parkinson's disease: A critical comparison and meta-analysis. J. Neurol. Neurosurg. Psychiatry 89(7), 687–691 (2017).
    1. Sheshadri V, Rowland NC, Mehta J, Englesakis M, Manninen P, Venkatraghavan L. Comparison of general and local anesthesia for deep brain stimulator insertion: A systematic review. Can. J. Neurol. Sci. 2017;44(6):697–704. doi: 10.1017/cjn.2017.224.
    1. MacIver MB, Bronte-Stewart HM, Henderson JM, Jaffe RA, Brock-Utne JG. Human subthalamic neuron spiking exhibits subtle responses to sedatives. Anesth. J. Am. Soc. Anesthesiol. 2011;115(2):254–264.
    1. Michelsen LG, Hug CC., Jr The pharmacokinetics of remifentanil. J. Clin. Anesth. 1996;8(8):679–682. doi: 10.1016/S0952-8180(96)00179-1.
    1. Shen W, Flajolet M, Greengard P, Surmeier DJ. Dichotomous dopaminergic control of striatal synaptic plasticity. Science. 2008;321(5890):848–851. doi: 10.1126/science.1160575.
    1. Schroll H, Hamker FH. Computational models of basal-ganglia pathway functions: Focus on functional neuroanatomy. Front. Syst. Neurosci. 2013;7:122. doi: 10.3389/fnsys.2013.00122.
    1. Steiner H, Gerfen C. Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons. Neuroscience. 1999;88(3):795–810. doi: 10.1016/S0306-4522(98)00241-3.
    1. Nisbet A, Foster O, Kingsbury A, Eve D, Daniel S, Marsden C, et al. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience. 1995;66(2):361–376. doi: 10.1016/0306-4522(94)00606-6.
    1. Samadi P, Bédard PJ, Rouillard C. Opioids and motor complications in Parkinson's disease. Trends Pharmacol. Sci. 2006;27(10):512–517. doi: 10.1016/j.tips.2006.08.002.
    1. Morissette M, Grondin R, Goulet M, Bédard PJ, Di Paolo T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J. Neurochem. 1999;72(2):682–692. doi: 10.1046/j.1471-4159.1999.0720682.x.
    1. Richardson SP, Egan TD. The safety of remifentanil by bolus injection. Expert Opin. Drug Saf. 2005;4(4):643–651. doi: 10.1517/14740338.4.4.643.
    1. Jhaveri R, Joshi P, Batenhorst R, Baughman V, Glass PS. Dose comparison of remifentanil and alfentanil for loss of consciousness. Anesthesiology. 1997;87(2):253–259. doi: 10.1097/00000542-199708000-00011.
    1. Schüttler J, Albrecht S, Breivik H, Osnes S, Prys-Roberts C, Holder K, et al. A comparison of remifentanil and alfentanil in patients undergoing major abdominal surgery. Anaesthesia. 1997;52(4):307–317. doi: 10.1111/j.1365-2044.1997.24-az0051.x.
    1. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord. 2010;25(15):2649–2653. doi: 10.1002/mds.23429.

Source: PubMed

3
Sottoscrivi